🎉 Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application


ATMA CEO and Team go live to share all things Psychedelic

Do you have questions regarding clinical trials, Oregon measure 109, Training, or anything related to psychedelics? 

As one of the leaders in the psychedelic field we want to support YOU on your way to providing these new treatments to your clients. 

This is your chance to engage in community, ask questions, and be part of the collective in guiding these treatments to the forefront of mental wellness. These sessions will be guided by ATMA’s CEO and will also be open to hearing from all participants in a unique collaboration of like-minded individuals. Psychedelics are coming and we need to discuss the best ways forward, the questions that need to be answered, and make sure that client safety and support is at the top of the list.